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ABSTRACT
Background and Objectives: The aim of this study was to compare the effects of a combination of niacin and simvastatin 
to simvastatin alone, on plaque regression and inflammatory makers. Subjects and Methods: The study had a prospective, 
randomized design. Subjects were patients with intermediate coronary artery stenosis. A total of 28 patients received a com-
bination of niacin 1,000 mg plus simvastatin 40 mg (N+S group, n=14); the other group received simvastatin 40 mg alone (S 
group, n=14). All patients had a baseline and a 9-month follow-up coronary angiogram and an intravascular ultrasound 
procedure. Parameters such as normalized total atheroma volume (nTAV) and percent atheroma volume (PAV) were analyz-
ed before and after treatment as were inflammatory markers such as high sensitivity C-reactive protein (hs-CRP), Matrix me-
talloproteinase-9 (MMP-9) and soluble CD40 ligand (sCD40L). Results: There was no difference in baseline characteristics 
between the two groups. The nTAV and PAV in the N+S group before and after treatment were not different than those in the 
S group. But the degree of changes (delta) in nTAV in the N+S group was greater than that in the S group (-21.6±10.68 vs. 
5.25±42.19, respectively, p=0.024). Also, the change in PAV in the NS group was higher than that in the S group (-1.2±2.5 
vs. -0.6±5, respectively, p=0.047. Changes in hs-CRP, MMP-9, and sCD40L in the NS group were significantly greater than 
those of the S group (-0.71±1.25, 73.5±64.9, -1,970±1,925 vs. -0.32±0.96, 62.5±30.6, -1,673±2,628, respectively). Conclu-
sion: The combination of niacin plus simvastatin decreases coronary plaque volume and attenuates the inflammatory re-
sponse in patients with intermediate coronary artery stenosis. (Korean Circ J 2011;41:641-648)
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Introduction
A family of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors known as statins reduce blood lev-
els of low density lipoprotein-cholesterol (LDL-C) and form 
the cornerstone of treatment of hyperlipidemia to reduce car-
diovascular morbidity and mortality.
1-4) Low serum concen-
trations of high density lipoprotein-cholesterol (HDL-C) are 
one of the major risk factors for adverse events related to co-
ronary atherosclerosis
5) and are highly prevalent among pa-
tients with acute coronary syndrome.
6) A previous study sh-
owed that each 1 mg/dL increase in HDL-C is associated with 
a 2% to 4% reduction in coronary heart disease (CHD) out-
comes.
5) According to the National Cholesterol Education 
Program, low levels of HDL-C (<40 mg/dL) have been identi-
fied as a coronary risk factor within the guidelines for treat-
ment of hyperlipidemia.
7) 
Niacin at pharmacologic doses reduces total cholesterol, 
triglycerides (TGs), very-low-density lipoprotein (VLDL), LDL-
C, and lipoprotein(a) {Lp(a)}, and increases HDL-C levels.
8)9) 
Of available lipid-regulating agents used to increase HDL lev-
els, Niacin is the most potent. Several studies demonstrate 
that treatment with niacin, alone or in combination with other 642   The Effects of Statin and Niacin on Plaque
lipid-lowering agents, significantly reduces total mortality and 
coronary events, and retards the progression and induces re-
gression of coronary atherosclerosis.
8)9) The HDL Atheroscle-
rosis Treatment Study (HATS) demonstrated that the com-
bined use of niacin and simvastatin dramatically improved 
angiographic end points and led to a significant reduction in 
clinical cardiovascular events (>80% decrease) and significant 
coronary stenosis regression compared with placebo.
10) The re-
cent ARBITER 2 and 3 trials showed that extended-release 
niacin significantly increases HDL-C and induces regression 
of atherosclerosis measured by carotid intima-media thickness 
(CIMT) when added to statin therapy.
11)12) But, there is little 
data that the combined effects of extended-release niacin and 
statin are synergistic in inducing regression of atherosclerosis 
measured by intravascular ultrasound (IVUS). Accordingly, 
the purpose of the present trial was to identify any synergy be-
tween niacin and simvastatin compared with simvastatin alone 
on plaque regression (measured by serial IVUS) and on inflam-
matory markers.
Subjects and Methods
Study population
This study was a pilot, prospective, randomized and open-
label study. It focused on coronary plaque regression in angi-
na patients who had mild to moderate degree of coronary ste-
nosis and who received niacin 1,000 mg plus simvastatin 40 
mg or simvastatin 40 mg alone. The hypothesis of this study 
was that the combination of niacin and simvastatin would cau-
se more regression of plaque than simvastatin alone, where pla-
que was measured by serial IVUS. The primary end point was 
the change in total and percent atheroma volume (TAV and 
PAV). Secondary end points were changes in high sensitivity C-
reactive protein (hsCRP), matrix metalloproteinase-9 (MMP-
9) and soluble CD40 ligand (sCD40L). Patients were ran-
domized to take either niacin 1,000 mg plus simvastatin 40 
mg or simvastatin 40 mg alone. Statin or combination thera-
py was started in both groups immediately after coronary 
angiography and IVUS. We enrolled a total of 28 patients 
(14 patients in the combined drug group vs. 14 in the simv-
astatin alone group) who underwent baseline and follow-up 
coronary angiography and IVUS. Inclusion criteria were: 
age 20 to 70, patients who had a mild to moderate degree of 
coronary stenosis measured by coronary angiogram and who 
had not been taking cholesterol lowering agents, hormone 
therapy or anti-oxidant vitamins within the previous 2 mon-
ths. We excluded premenopausal women, individuals young-
er than 20 years or older than 70 years, those with hypercho-
lesterolemia (type I, III, IV, V), homozygous familial hy-
percholesterolemia, those using cholesterol lowering agents 
(HMG-CoA reductase inhibitors, bile acid sequestrants and 
nicotinic acid within 6 weeks, fibrate within 8 weeks, probucol 
within 1 year), the use of cyclosporine or antifungal agents 
(azole), severe left ventricular dysfunction (an ejection frac-
tion <35%), active liver disease or hepatic dysfunction {ala-
nine aminotransferase (ALT) and aspartate aminotransferase 
(AST) >20% of the normal value}, renal dysfunction (serum 
serum creatinine >1.8 mg/dL), hypothyroidism, secondary hy-
percholesterolemia due to nephrotic syndrome, partial ileal 
bypass, hypersensitivity to a HMG-CoA reductase inhibitor 
or an ACE inhibitor and participation in another clinical tri-
al. A mild to moderate degree of coronary stenosis was de-
fined as a stenotic diameter of 30% to 60% of normal, and 
was assessed by quantitative coronary angiography. After the 
9-month treatment period, the patients underwent repeated 
cardiac catheterizations and IVUS examinations of the ma-
tched segments under identical conditions. This study’s pro-
tocol was approved by the institutional review board of Gil 
Medical Center, Gachon University of Medicine and Science 
and informed consent was obtained from all patients. 
Methods
Study process
After informed consent was obtained, subjects were ran-
domized (allocation concealed) in a 1 : 1 fashion to receive 
either niacin 1,000 mg plus simvastatin 40 mg or simvastatin 
40 mg alone. Randomization was done with a computer-gen-
erated sequence of random numbers. Study medication was 
initiated at a daily dose of 500 mg for 30 days, which was then 
increased to 1,000 mg for the duration of the 9-month study 
period. The study medication was taken at night, and it was 
recommended that it be taken with the subjects’ usual daily 
dose of anti-anginal medication. All patients taking other me-
dications such as fish-oil more than 200 mg/day, antacid, anti-
coagulant, immune depressant, corticosteroid, erythromycin, 
clarithromycin, systemic itraconazole and ketoconazole were 
strongly encouraged to discontinue their use of these supple-
ments during the study to avoid possible interference with the 
response to niacin. The authors decided the dose of niacin bas-
ed on a recent study and the dose of statin based on highest 
tolerable dose to Koreans.
Laboratory analysis
For all patients, serum samples were collected before coro-
nary angiography for measuring lipid profiles, hs-CRP, blo-
od urea nitrogen (BUN), creatinine, AST andALT. Serum levels 
of total cholesterol, LDL-C, HDL-C and TG were measured by 
standard enzymatic methods. hs-CRP was analyzed using com-
mercial kits containing a nephrometry system. MMP-9 and 
sCD40L were analyzed using commercially available ELISA 
kits. Serum levels of total cholesterol, LDL-C, HDL-C, TGs, 
hs-CRP, BUN, creatinine, AST and ALT were measured at 
baseline and at 9-month follow-up. Kyounghoon Lee, et al.   643
Intravascular ultrasound imaging and analysis
Intravascular ultrasound imaging and analysis was done 
at baseline and at the 9-month follow-up. IVUS examina-
tions were done after intracoronary administration of 200 μg 
nitroglycerin using a commercially available IVUS system 
(Boston Scientific Corporation/SCIMed, Minneapolis, MN, 
USA). The IVUS catheter was advanced distal to the target le-
sion, and imaging was done retrograde to the aorto-ostial 
junction at an automatic pullback speed of 0.5 mm/s. The 
same anatomic image slices were analyzed at baseline and at 
follow-up. By using axial landmarks (i.e., side branches, cal-
cifications or unusual plaque shapes) and the known pullback 
speed, identical cross-sectional image slices on serial studies 
could be identified for making comparisons. We measured 
IVUS images that were precisely spaced 1 mm apart. The le-
ading edges of the external elastic membrane (EEM) and lu-
men were traced manually in accordance with the guidelines 
for IVUS of the American College of Cardiology Clinical Ex-
pert Consensus Document on Standards for the Acquisition, 
Measurement and Reporting of Intravascular Ultrasound Stu-
dies.
13) The total atheroma volume (TAV) was calculated by 
summation of the atheroma areas from each measured image: 
TAV=Σ (the EEM area-the lumen area). The PAV was deter-
mined using the formula: PAV= 100×{Σ (the EEM area-the 
lumen area)/Σ (EEM areas)}.
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) for 
Windows, version 12.0 (Chicago, IL, USA) was used for all 
analyses. Continuous variables are presented as mean val-
ues±standard deviations (SDs); they were compared using 
paired or unpaired Student’s t-tests or the nonparametric Wil-
coxon test if the normality assumption was violated. Discrete 
variables are presented as percentages and relative frequen-
cies. A repeated measured analysis of variance (ANOVA) test 
was used for comparing continuous variables before and after 
treatment. Linear regression analysis was used to evaluate as-
sociations between continuous variables. A p<0.05 was con-
sidered statistically significant.
Results
Baseline characteristics
There was a total of 28 subjects. Mean age was 60.8±8.0 years 
in the simvastatin group and 58.1±7.0 years in the niacin/si-
mvastatin group. Seven patients (50%) in the simvastatin gr-
oup and 7 patients (50%) in the niacin/simvastatin group were 
males. No patients dropped out because of side effects to ni-
acin or simvastatin. There was no difference in risk factors 
such as diabetes mellitus, hypertension, smoking and clinical 
diagnosis between the two groups. Ejection fraction on echo-
cardiograms and results from coronary angiograms were not 
different between the two groups (Table 1). Laboratory find-
ings between the two groups were not different (Table 2). 
Comparison of coronary angiograms and 
intravascular ultrasound findings between 
the two groups
A paired t-test showed no difference in the coronary angio-
gram or in the IVUS before and after treatment (Table 3). Re-
peated measured ANOVA adjusted by the initial measurement 
and changes showed a statistically significant difference. The 
Table 1. Baseline characteristics of study patients
Statin group (n=14) Niacin/Statin group (n=14) p
Age (years) 060.8±8.0 058.1±7.0 0.359
Height (cm) 160.8±7.8 157.6±8.4 0.310
Weight (kg) 063.5±8.5 0063.5±10.6 0.983
Male (%) 7 (50.0) 7 (50.0) 1.000
Dx. SA (%) 7 (50.0) 5 (35.7) 0.689
UA (%) 6 (42.9) 7 (50.0)
AMI (%) 1 (7.1) 2 (14.3)
Risk CVA (%) 0 (0) 1 (7.1) 0.144
MI (%) 0 (0) 0 (0)
DM (%) 8 (57.1) 5 (35.7) 0.256
Hypertension (%) 4 (28.6) 5 (35.7) 0.686
Smoke (current) (%) 3 (21.4) 5 (35.7) 0.403
Procedures Previous PCI 3 (21.4) 1 (7.1) 0.280
Target vessel (%) (LAD/LCX/RCA/LM) 66.7/11.1/22.2/0 85.7/14.3/0/0 0.283
Dx.: Diagnosis, SA: stable angina, UA: unstable angina, AMI: acute myocardial infarction, CVA: cerebrovascular accident, MI: myocardial in-
farction, DM: diabetes mellitus, PCI: percutaneous coronary intervention, LAD: left anterior descending artery, LCX: left circumflex artery, RCA: 
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normalized total atheroma volume (nTAV) before treatment 
was 170.6±63.6 in the simvastatin group and 201.3±66.9 in 
niacin/simvastatin group (p=0.364). The nTAV after treat-
ment was 175.9±46.9 in simvastatin group and 179.7±63.8 
in the niacin/simvastatin group (p=0.891). Changes in nTAV 
were significantly different (p=0.024) (Fig. 1) (Table 4). The 
PAV before treatment was 45.4±9.6 in the simvastatin group 
and 49.8±10.7 in the niacin/simvastatin group (p=0.407). The 
PAV after treatment was 44.3±9.9 in the simvastatin group 
and 48.6±12.4 in the niacin/simvastatin group (p=0.451). Ch-
anges in PAV were significantly different (p=0.047) (Figs. 2 
and 3) (Table 4). 
Comparison of biomarkers of inflammation and 
oxidative stress between the two groups
After 9 months, hsCRP decreased in the simvastatin group, 
from 0.661±1.298 mg/dL to 0.341±0.573 mg/dL and decreas-
ed in the niacin/simvastatin group from 0.894±1.233 mg/dL 
to 0.186±0.351 mg/dL (p=0.001) (Fig. 4) (Table 4). After 9 
months, MMP-9 increased in the simvastatin group from 
Table 2. Laboratory characteristics of study patients
Statin group (n=14) Niacin/Statin group (n=14) p
SBP (mm Hg) 118.6±14.90 120.9±16.00 0.691
DBP (mm Hg) 72.0±8.90 72.3±11.7 0.943
HR (per minute) 69.4±11.6 71.7±9.40 0.572
LVEF (%) 65.5±7.90 59.7±8.70 0.094
Total cholesterol (mg/dL) 204.6±36.30 190.9±5.300 0.275
TG (mg/dL) 147.9±83.40 171.9±137.6 0.582
HDL-C (mg/dL) 48.6±10.0 49.0±5.30 0.907
LDL-C (mg/dL) 127.1±23.50 116.0±33.50 0.320
WBC (/mm
3) 6953.6±1541.7 7620.0±1792.2 0.301
Fasting glucose (mg/dL) 119.2±66.30 111.9±28.10 0.709
Insulin (mg/dL) 22.6±51.1 12.4±10.6 0.471
hsCRP (mg/dL) 0.66±1.29 0.85±1.19 0.702
Fibrinogen (pg/dL) 427.1±168.0 458.3±104.1 0.560
MMP-9 (ng/mL) 10.0±9.80 11.2±6.20 0.715
sCD40L (ng/L) 2634.0±1594.8 2803.6±2033.5 0.815
SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, TG: triglyceride, HDL-C: high density lipoprotein-cholesterol, LDL-
C: low density lipoprotein-cholesterol, WBC: white blood cell, hs-CRP: high-sensitivity C-reactive protein, MMP-9: matrix metalloproteinase-9, 
sCD40L: soluble CD 40 ligand
Table 3. Angiogram and IVUS before and after treatment
Statin
group
(n=14)
Niacin/
Statin group
(n = 14)
p
Proximal RD
  (mm
2)
Pre 03.09±0.42 02.93±0.52 0.534
Post 03.07±0.39 03.09±0.55 0.943
MLD (mm) Pre 02.11±0.49 01.74±0.31 0.100
Post 02.13±0.44 02.03±0.32 0.620
Distal RD
   (mm)
Pre 02.73±0.46 02.66±0.36 0.753
Post 02.68±0.59 02.75±0.25 0.771
Lesion length
   (mm)
Pre 17.1±6.3 023.3±12.3 0.251
Post 17.0±6.2 023.3±12.2 0.204
Lumen CSA
   (mm
2)
Pre 06.31±2.11 05.92±0.82 0.647
Post 06.57±1.55 05.54±0.95 0.146
EEM CSA
  (mm
2)
Pre 11.49±3.35 12.01±1.71 0.710
Post 11.70±2.08 10.98±1.33 0.439
Atheroma CSA
   (mm
2)
Pre 05.17±1.93 06.11±2.03 0.360
Post 05.22±1.38 05.45±1.92 0.784
nTAV Pre 170.6±63.6 175.9±66.9 0.364
Post 175.9±46.9 179.7±63.8 0.891
% AV Pre 45.4±9.6 049.8±10.7 0.407
Post 44.3±9.9 048.6±12.4 0.451
RD: reference diameter, MLD: minimal luminal diameter, CSA: 
cross-sectional area, EEM: external elastic membrane, nTAV: nor-
malized total atheroma volume, AV: atheroma volume
9 month C-angio and IVUS
Randomization (n=28)
Enrollment (n=28)
Eligible patients (n=60)
No drop out due to
drug side effect
Exclusion: 32 patietns
  not informed consent
  exclusion criteria
Group 1 (n=14)
Statin group
Group 2 (n=14)
Statin/Niacin group
Fig. 1. Flow diagram of the study.Kyounghoon Lee, et al.   645
10.2±9.8 to 72.5±33.9 and increased in the niacin/simvas-
tatin group from 11.2±6.2 to 84.7±63.3 (p=0.017) (Fig. 5) (Ta-
ble 4). After 9 months, sCD40L decreased in the simvastatin 
group from 2,634±1,594 to 961±1,529 and decreased in the 
niacin/simvastatin group from 2,803±2,033 to 836±1,034 
(p<0.001) (Fig. 6) (Table 4). 
Discussion
The present study demonstrates that lipid lowering therapy 
with niacin plus simvastatin induces significant plaque re-
gression and stabilization in angina patients who had a mild 
to moderate degree of coronary stenosis. The main focus of the 
present study was to show that the combination of niacin plus 
simvastatin showed a greater decrease in the TAV and the 
PAV measured by IVUS, a greater decrease in inflammatory 
response measured by biomarkers, and a greater decrease in 
platelet activation as measured by sCD40L (Fig. 7).
Currently, the treatment of lipid abnormalities involves the 
Table 4. Changes in IVUS parameters and biomarkers
Statin group (n=14) Niacin/Statin group (n=14) p
nTAV Baseline 170.6±63.6 201.3±66.90 0.364
Post-treatment 175.9±46.9 179.7±63.80 0.891
Δ changes 0.5.25±42.19 -21.6±10.68 0.024
PAV Baseline 45.4±9.6 49.8±10.7 0.407
Post-treatment 44.3±9.9 48.6±12.4 0.451
Δ changes -0.6±5.0 -1.2±2.50 0.047
hsCRP Baseline 00.66±1.29 0.85±1.19 0.702
Post-treatment 00.34±0.57 0.19±0.35 0.409
Δ changes -0.32±0.96 -0.71±1.250 0.001
MMP-9 Baseline 10.0±9.8 11.2±6.20 0.715
Post-treatment 072.5±33.9 84.7±63.3 0.549
Δ changes 062.5±30.6 73.5±64.9 0.017
sCD40L Baseline 02,634.0±1,594.8 2,803.6±2,033.5 0.815
Post-treatment 0961±1,529 0833±1034 0.805
Δ changes -1,673±2,628 -1,970±1,9250 0.001
nTAV: normalized total atheroma volume, Δ changes: post-treatment-baseline, PAV: percent atheroma volume, hs-CRP: high-sensitivity C-
reactive protein, MMP-9: matrix metalloproteinase-9, sCD40L: soluble CD 40 ligand
Fig. 2. Changes in the normalized total atheroma volume before 
and after treatment.
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Fig. 3. Percent changes in atheroma volume before and after treat-
ment.
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primary use of statins to reduce serum levels of LDL-C. Mul-
tiple studies have shown that statins lower the mortality and 
morbidity of patients with coronary artery disease and other 
atherosclerotic vascular diseases.
1-4) Statins effectively inhibit 
mevalonate synthesis and lower LDL-C levels. Beyond lower-
ing the blood lipoprotein level, statins have favorable effects 
on vascular inflammation,
14) endothelial function,
15) and plaque 
regression.
16-18) Despite substantial reductions in cardiovas-
cular morbidity and mortality that have been achieved with 
statins, the protection afforded by these drugs is incomplete. 
Thus, combination therapies directed at increasing HDL-C 
are an attractive but unproven approach. This study was the 
first demonstration of an incremental, independent effect of 
combination therapy with statin and niacin compared with st-
atin monotherapy to retard the progression of atherosclero-
sis as measured by IVUS in Korean patients. 
Fig. 5. Changes in MMP-9 before and after treatment. MMP-9: ma-
trix metalloproteinase-9.
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Fig. 6. Changes in sCD40L before and after treatment. sCD40L: so-
luble CD 40 ligand.
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Fig. 7. Images before and after treatment for the Statin group (A) 
and the Statin/Niacin group (B).
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Fig. 4. Changes in hsCRP before and after treatment. hsCRP: high-
sensitivity C-reactive protein.
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Niacin has been in clinical use for 4 decades and is the most 
effective treatment currently available to increase low levels 
of HDL-C. The current understanding of its place in an era of 
potent therapies directed at LDL-C was limited by a lack of stu-
dies assessing its incremental effect on atherosclerosis and co-
ronary outcomes. The most recent demonstration of this was 
the HATS.
19) This placebo-controlled study of combined low-
dose simvastatin (10 to 20 mg/d) and high dose niacin (2 to 
4 mg/d) showed the ability of combination therapy to largely 
stabilize coronary atherosclerosis with an associated substan-
tial 13% absolute risk reduction (up to 90% relative risk reduc-
tion) for cardiovascular outcomes. The absence of a statin mo-
notherapy control group and the use of relatively high doses 
of niacin, however, limit the capacity to extrapolate the data to 
a stepwise additive approach to combination therapy in clini-
cal practice that might typically use lower doses of niacin. The 
data from ARBITER 2 extended our understanding of the 
potential benefit of combination therapy with statin and nia-
cin in patients with known CHD and moderately low levels of 
HDL-C beyond multiple previous studies that included nia-
cin as a component of combination therapy.
20) ARBITER 2 sh-
owed a significant progression of carotid intima media th-
ickness (CIMT) in the placebo (statin monotherapy) group, 
despite a mean LDL-C of 100 mg/dL, a result that was consis-
tent with previous placebo-controlled studies of statin mono-
therapy and atherosclerosis progression.
11)12)20) Such progres-
sion of atherosclerosis in the setting of a statin administered 
long term differed from the observed initial results of statin ad-
ministration, likely due to the influence of other lipids (e.g., 
low HDL-C) and non-lipid risk factors.
Recent data showed that enhanced sCD40L is associated 
with platelet activation in the setting of hypercholesterolemia, 
related to an increase in sCD40L to the prothrombotic state 
previously described in hypercholesterolemia, and provided 
in vivo evidence that statins might significantly reduce sCD40L 
and the CD40L-associated prothrombotic state.
21) The present 
study shows that combination therapy of niacin plus simvasta-
tin decreases sCD40L and supports the inhibition of plaque 
progression.
There is evidence that CRP has proinflammatory and pro-
atherogenic effects via modulation of endothelial, inflamma-
tory and smooth muscle cells of the arterial wall. The proin-
flammatory, proatherogenic effects of CRP that have been 
documented in endothelial cells include: 1) decreased nitric 
oxide and prostacyclin production, and 2) increased pro-
duction of endothelin-1, cell adhesion molecules, monocyte 
chemoattractant protein-1, IL-8, and plasminogen activator 
inhibitor-1.
22)23) The present study shows that combination 
therapy of niacin plus simvastatin decreases hsCRP and ex-
plains the inhibition of atherosclerosis progression.
In soft, lipid-rich plaques, especially ones obtained from pa-
tients who died of acute coronary syndrome, inflammatory 
cells including activated macrophages and mast cells accumu-
late in high concentration. There is an increased rate of forma-
tion of MMP enzymes in the ruptured atherosclerotic plaque. 
Active rupture of the vulnerable plaque by these proteinases is 
one of the triggers causing subsequent thrombus formation 
and acute coronary syndrome. This is clinically significant 
because, serial changes in peripheral blood levels of MMP-2 
and MMP-9 were observed in patients with acute coronary 
syndrome, which implicates a role for these enzymes in the mo-
lecular mechanism of plaque destabilization in acute coronary 
syndrome. Macrophages and smooth muscle cells of human 
atherosclerotic plaques have been shown to synthesize MMP-
3 and MMP-9.
24) MMP-9 might directly affect thrombus mat-
uration and dissolution. MMP-9 was able to inhibit platelet ag-
gregation in response to thrombin or collagen
25) and can de-
grade fibrin.
26) Furthermore, thrombus formation can induce 
MMP-9 release from surrounding cells,
27) and MMP-9 knock-
out mice have an increased propensity to hemorrhage.
28) There-
fore, MMP-9 can reduce thrombus size, and its increased ex-
pression may promote smooth muscle cell-directed healing 
after atherosclerotic plaque rupture, resulting in retardation of 
plaque expansion and increased stability of the newly forming 
cap. Another study showed that MMP-9-dependent processes 
are activated that initiate a healing response that is involved in 
the recruitment of smooth muscle cells and in the elaboration 
of matrix when an acute plaque rupture takes place. Hence, 
after an acute coronary event, increases in the plasma MMP-
9 concentration might be the consequence of a healing re-
sponse rather than of the initial plaque rupture.
29) The present 
study showed that combination therapy of niacin plus simv-
astatin increases MMP-9 and explains the plaque stabiliza-
tion as do the other biomarkers.
The present study has two limitations. First, the study size 
was relatively small. Second, there was selection bias due to 
patients being enrolled in a single center. In spite of the limita-
tions, the present study shows two important differences. First, 
this is the first study, to our knowledge, to show a combined 
effect of statin and niacin using IVUS parameters in Koreans. 
Second, the present study shows the additive effect of niacin 
to high dose statin therapy.
In conclusion, the combination of niacin plus simvastatin 
reduces TAV and PAV measured by IVUS, reduces inflamma-
tory responses measured by biomarkers and decreases platelet 
activation measured by sCD40L.
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